Acurian receives 2010 Lilly Global Supplier Award

Award recognizes Acurian’s delivery of superior results and service to Eli Lilly and Company

INDIANAPOLIS--(BUSINESS WIRE)-- Acurian, Inc., a leading, full-service provider of global patient recruitment and retention solutions, was selected by Eli Lilly and Company for their 2010 Lilly Global Supplier Award. The award was presented to Acurian executives in a ceremony at the company's headquarters in Indianapolis on April 12.

The Lilly Global Supplier Award recognizes suppliers who have worked collaboratively to deliver a positive and measurable impact on Lilly’s corporate objectives and priorities. The annual award is given to suppliers who exemplify the delivery of quality, service, speed, total cost reduction, and value.

“We are deeply honored and proud to receive this award from our valued customer,” said Acurian CEO Rick Malcolm. “This award recognizes our company’s outstanding and talented employees who consistently strive to make Acurian the global standard in efficiency, predictability, and performance.”

About Acurian

Acurian is a leading full-service provider of clinical trial patient recruitment and retention solutions for the life sciences industry. Through its proprietary patient panel of over 65 million patients, centralized advertising capabilities, and a fully hosted enrollment management technology platform, Acurian is able to identify, contact, prescreen, and refer patients into clinical trials across the globe, all while supporting investigator sites with services to maximize the randomization potential of every referred patient. Since 1998, Acurian has supported over 400 protocols for more than 60 companies. Acurian's investors include Euclid SR Partners, ProQuest Investments, JP Morgan Partners, Flatiron Partners, CDP Capital Technology Ventures, and Merck Capital Ventures.

For more information

Visit www.acurian.com; or contact Scott Connor, VP Marketing, at [email protected] or 215-323-9028.



CONTACT:

Acurian, Inc.
Scott Connor, Vice President, Marketing
215-323-9028
[email protected]

KEYWORDS:   United States  North America  Indiana  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Medical Devices  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.